Overexpression
When a cell makes much more of a particular protein than normal cells do. Drugs that home in on that protein can then hit the tumour harder than healthy tissue.
Overexpression can result from gene amplification, from a mutation in the gene's control region, or from signalling that keeps the gene switched on. It is what makes many antibody and ADC targets useful: TROP2, HER2, Nectin-4 and B7-H3 are all present at low levels on some normal cells but at far higher levels on particular tumours, so a targeted drug concentrates where the target is densest. Overexpression is scored by immunohistochemistry (0, 1+, 2+, 3+), and the threshold that counts as 'positive' can change as drugs improve, as happened with HER2-low.
Pages like this
not linked directly; found by shared links- IdeaAlpha radioligands after ADC failure
Shares B7-H3, TROP2, HER2, Antibody-drug conjugate (ADC).
- CompanyAvenzo Therapeutics
- IdeaRe-map the tumour's surface proteins before choosing the next antibody drug
Shares B7-H3, TROP2, HER2, Antibody-drug conjugate (ADC).
- CompanyDuality Biotherapeutics
- CompanyAktis Oncology
- IdeaRe-test the metastasis, not the old primary, before every change of treatment
Shares Immunohistochemistry (IHC), HER2-low and HER2-ultralow.
- IdeaDual-payload ADCs in first line to prevent resistance
Shares TROP2, HER2, Antibody-drug conjugate (ADC).
- TermProtein